MyFinsight
Home
Blog
About
Net income
$1,296,900K
(-6.81%↓ Y/Y)
Net cash provided by
operating activities
$813,000K
(-28.96%↓ Y/Y)
Canceled cashflow
$483,900K
Increase in accounts
payable, accrued...
$492,700K
(127.68%↑ Y/Y)
Stock-based compensation
expense
$243,000K
(-3.46%↓ Y/Y)
Depreciation and
amortization
$123,700K
(-8.44%↓ Y/Y)
Other, net
-$54,900K
(-362.68%↓ Y/Y)
Increase (decrease) in
deferred revenue
$43,900K
(130.72%↑ Y/Y)
Net decrease in
cash, cash...
-$504,600K
(53.17%↑ Y/Y)
Canceled cashflow
$813,000K
Proceeds from issuance of
common stock
$49,200K
(56.19%↑ Y/Y)
Sales or maturities of
marketable and other...
$2,148,600K
(-0.89%↓ Y/Y)
Total adjustments
-$483,900K
(-95.75%↓ Y/Y)
Canceled cashflow
$958,200K
Net cash used in
financing activities
-$1,224,600K
(-8.54%↓ Y/Y)
Canceled cashflow
$49,200K
Net cash used in
investing activities
-$92,700K
(91.53%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
-$300K
(-175.00%↓ Y/Y)
Canceled cashflow
$2,148,600K
(increase) decrease in
accounts receivable
$838,500K
(2873.40%↑ Y/Y)
Increase in prepaid
expenses and other assets
$319,100K
(38.32%↑ Y/Y)
Deferred income taxes
$194,400K
(43.79%↑ Y/Y)
Gains on marketable
and other...
$61,900K
(-75.24%↓ Y/Y)
Increase in inventories
$28,200K
(-33.65%↓ Y/Y)
Repurchases of common stock
$1,169,400K
(10.16%↑ Y/Y)
Dividends paid
$96,800K
(4.54%↑ Y/Y)
Payments in connection
with common stock...
$7,600K
(35.71%↑ Y/Y)
Purchases of marketable
and other...
$1,950,100K
(-31.70%↓ Y/Y)
Capital expenditures
$240,200K
(9.68%↑ Y/Y)
Payments for intangible
assets
$51,000K
(-72.84%↓ Y/Y)
Back
Back
Cash Flow
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
REGN_BIG copy-svg-svg-svg
REGENERON PHARMACEUTICALS, INC. (REGN)
source: myfinsight.com